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ABSTRACT 
 
RNA  interference-mediated  gene  silencing  offers  the  potential  of  targeted  inhibition  of  disease-relevant 
genes. In vivo delivery of RNAi reagents can be obtained by a variety of approaches. Physical delivery 
methods  appear  safer  and  lack  side  effects.  Electro-permeabilization  is  one  of  the  non-viral  methods 
successfully used to transfer small interfering RNAs (siRNAs) in vitro and in vivo. A promising approach 
may be, very little is known about the fundamental processes mediating siRNA transfer. In this study, we 
have investigated cellular delivery pathways involved in electro-delivery of siRNAs by a direct fluorescence 
imaging  method.  An  Alexa-labeled  siRNA  was  electro-transferred  into  murine  melanoma  cells  stably-
expressing the enhanced green fluorescent protein (eGFP) target reporter gene. The silencing of eGFP gene 
expression  was  quantified  by  time-lapsed  fluorescence  microscopy.  Fluorescently-labeled  siRNAs  were 
found  distributed  homogeneously  in  cytoplasm  48  hours  after  electro-transfer,  apparently  by  diffusion. 
Furthermore, siRNAs showed homogeneous distribution in vivo 48 hrs after intra-tumoral injection followed 
by  electro-  permeabilization.  Histological  fluorescence  microscopy  showed  that  siRNAs  were  mostly 
localized in the cytoplasm. Overall, this study shows that electro-permeabilization facilitates cytoplasmic 
distribution of siRNA, both in cultured cells and in vivo. This method offers a potential therapeutic tool to 
facilitate direct siRNA penetration into solid tumors. 
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INTRODUCTION 
 
RNA  interference  offers  a powerful  approach to silence 
post-transcriptional gene expression (Fire et al, 1998) and 
thus have considerable therapeutic potential (Novina and 
Sharp, 2004; Akhtar and Benter, 2007). The future use of 
siRNA  as  therapeutics  will  largely  rely  on  the 
development of efficient in vivo delivery methods, which 
remains  a  major  challenge  (Rossi,  2005;  Ryther  et  al, 
2005;  Aigner,  2007).  A  safe  siRNA  delivery  approach 
requires  direct  transfer  of  molecules  to  the  cytoplasm, 
avoiding off-target interactions associated with the cellular 
uptake pathways (Heidel et al, 2004). Electric pulses are 
known  to  strongly  stimulate  cellular  uptake  of  various 
drugs  that  otherwise  show  intrinsically  poor  cellular 
delivery. Electric pulses have also been frequently used to 
deliver drug, siRNAs and plasmids into organs and tissues, 
in vivo (Li, 2004; Wells, 2004; Golzio et al, 2005; Golzio 
et al, 2007). In rodents, electric pulses have been used to 
deliver siRNAs into various organs, such as skin (Zhang et 
al,  2002),  eyes  (Matsuda  and  Cepko,  2004),  brain 
(Akaneya  et  al,  2005),  muscles  (Golzio  et  al,  2005;  
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Kishida et al, 2004), joint tissue (Inoue et al, 2005) and 
kidneys  (Takabatake  et  al,  2005).  However,  electro-
delivery  of  large  nucleic  acids  (e.g.,  plasmids)  is  less 
efficient in solid tumors (Rols et al, 1998; Coralli et al, 
2001; Cemazar et al, 2002). Electro-delivery offers several 
specific advantages: for example, delivery of molecules is 
restricted  to  the  volume  where  the  electric  field  is 
generated  (Miklavcic  et  al,  1998);  pulse  parameters  are 
fully and easily controlled; very few side effects have been 
reported for these treatments emphasizing the suitability of 
this physical method for clinical use. 
 
Studies on electro-chemotherapy and electro-genotherapy 
to  enhance  the  delivery  of  small  molecule  drugs  and 
nucleic acids, respectively, are currently underway (e.g., 
ESOPE and Angioskin European projects). Previously, we 
generated B16-F10 melanoma cell line stably-expressing 
enhanced  green  fluorescent  protein  (eGFP)  and  showed 
that  electrical  treatment  led  to  siRNA-mediated 
endogenous gene silencing in solid tumors (Golzio et al, 
2007). In this study, in order to assess the intra-cellular 
distribution of siRNAs, we compared in vitro and in vivo 
efficacy  in  gene  silencing  by  electro-transferred 
fluorescent and non fluorescent siRNA. We then followed 
the  intra-cellular  localization  of  fluorescently-labeled 
siRNA in cultured cells and in solid tumors, in vivo. 
 
MATERIALS AND METHODS 
 
Cell culture 
B16-F10 melanoma cells expressing the enhanced Green 
fluorescent  protein  (B16F10-eGFP),  produced  by 
retroviral  transduction  (see  Cemazar  et  al,  2006)  were 
maintained  in  Eagle’s  minimum  essential  medium 
(EMEM; Gibco-Invitrogen, USA) with  10%  (v/v)  foetal 
calf  serum  (Gibco),  penicillin  (100  units/ml,  Gibco–
Invitrogen), streptomycin (100 mg/ml, Gibco-Invitrogen) 
and L-glutamine (0.58 mg/ml, Eurobio, France) in a 5% 
(v/v) CO2 humidified incubator at 37°C (Jouan, France). 
 
siRNAs 
All siRNAs were purchased from Qiagen Xeragon (USA). 
The eGFP22 siRNA (sense: 5‘GCAAGCUGACCCUGAA 
GUUCAU, antisense: 5’GAACUUCAGGGUCAGCUUG 
CCG)  was  directed  against  eGFP  mRNA  and  was 
designed according to Caplen and coworkers (Caplen et al, 
2001).  To  determine  the  localization  of  siRNA,  a 
fluorescent Alexa Fluor 546 labeled siRNA was used. The 
P76  siRNA  (sense:  5’GCGGAGUGGCCUGCAGGUA 
dTdT,  antisense:  5’  UACCUGCAGGCCACUCCGC 
dTdT)  was  directed  against  an  unrelated  human  mRNA 
and shows no significant homology to mouse transcripts 
according to Basic Local Alignment Search Tool analysis. 
It  was  used  as  a  control  for  specificity  of  the  siRNA 
constructs. 
 
Permeabilization of cultured cells and electro-transfer 
of siRNAs  
The penetration of Propidium Iodide (100 µM in a pulsing 
buffer: 10 mM phosphate, 1 mM MgCl2, 250 mM sucrose, 
pH 7.4) (Sigma) was used to monitor permeabilization. 100 
µl of the cell suspension (i.e., 5x10
5 cells) in the pulsing 
buffer was placed in electro-pulsation chamber, which was 
designed using stainless steel parallel plates electrodes (10 
mm  length,  0.5  mm  thick  and  4  mm  inter-electrode 
distance) brought in contact to the bottom of a 35 mm Petri 
dish (Nunc, Denmark). Electro-pulsation (EP) was operated 
by  using  a  CNRS  cell  electro-pulsator  (Jouan),  which 
delivered  square-wave  electric  pulses.  An  oscilloscope 
(Enertec, France) monitored pulse shape online. A uniform 
electric field  was  generated when the  voltage  pulse was 
delivered. Ten pulses with controlled duration of 5 ms, at a 
frequency  of  1  Hz,  were  applied  at  preset  electric  field 
intensities  at  room  temperature  (25°C).  Membrane  re-
sealing  occurred  5  min  after  pulse  application,  keeping 
internalized  dyes  trapped.  Cells  were  analyzed  by  flow 
cytometry (Becton Dickinson FACScan) to determine the 
percentage  of  permeablized  cells  (i.e.,  fluorescent  cells). 
Cell viability 24 hrs after the treatment was determined by 
coloration using Crystal Violet (Merck, Germany). 
 
Electro-transfer of siRNAs was performed using optimum 
parameters for cell permeabilization. Cells in suspension 
(5x10
5  cells)  were  transfected  with  2  µg  of  siRNA  in 
pulsing  buffer  under  the  same  conditions  as  for 
permeabilization.  Cells  were  then  analyzed  by  flow 
cytometry  in  order  to  determine  the  percentage  of  cells 
expressing  the  eGFP,  and  their  associated  fluorescence 
intensity.  Cells  were  then  treated  with  siRNAs  and 
electrical pulses, and were sorted out by flow cytometry 
(FACScalibur, Becton Dickinson) 48 hrs after treatment to 
identify silenced cells with silenced eGFP. Selected cells 
were observed under a microscope. 
 
Cell Viability analysis 
Cell  viability  was  determined  by  the  ability  of  cells  to 
grow  and  divide  over  a  24  hour  period  (Gabriel  and 
Teissie, 1995). Cells were pulsed, kept for 10 min at 30
oC 
and then grown on Petri dishes after adding 1 ml of culture 
medium for 24 hrs at 37
oC, in a 5% (v/v) CO2 incubator. 
Viability  was  measured  by  counting  cells  with  the 
coloration method as above. 
 
Mouse tumor model 
Female  C57Bl/6  mice were  obtained from  Rene Janvier 
(St  Isle,  France)  and  were  subjected  to  an  adaptation 
period  of at least 10 days before experimentation.  They 
were maintained at a constant room temperature with a 12 
hrs light cycle in a conventional animal facility. The mice 
were 10-14 weeks old at the beginning of the experiments 
weighing 20-25 g. Tumors were implanted subcutaneously 
in  the  right  flank  of  the  mice  by  inoculation  of  10
6 
B16F10-eGFP cells in PBS and grown to a size of 5-7 mm 
in diameter. All procedures were performed with approved 
protocols, in accordance with the French CNRS and EU 
commission regulations for laboratory animals’ care. 
 
In vivo electro-pulsation 
Fifty µl of saline solution (i.e., PBS containing 40 U of the 
RNase inhibitor, RNAsin) (Promega, USA) and either 12 
µg of eGFP22 or of p76 siRNA were slowly injected (for 
about  15  sec)  with  a  Hamilton  syringe  through  a  26G 
needle (Hamilton, Switzerland) into the tumor, under 2% 
(v/v) isoflurane anesthesia. In the control conditions, the 
volume  of  siRNA  was  replaced  by  siRNA  suspension 
buffer  to  keep  the  injection  conditions  similar.  Electro- 
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pulsation was applied 30 sec after injection. Parallel plate 
electrodes  (length  1  cm,  width  0.6  mm,  inter-electrode 
distance 6 mm) (IGEA, Italy) were fitted around the tumor 
that  had  been  previously  shaved  with  a  cream  (Veet, 
Reckitt & Colman, France). A good electric contact was 
achieved  between  the  skin  and  the  electrodes  using  a 
conducting  paste  (Eko-gel,  Italy).  Electrical  parameters 
were  defined  by  taking  pulse  duration  into  special 
consideration,  which  appears  critical  for  nucleic  acid 
electro-transfer,  Pulses  with  reverse  polarities  were  also 
used to help  electro-delivery  by  taking  advantage  of the 
vectorial  character  of  the  electric  field.  Square-waved 
pulses were delivered as described previously (Golzio et al, 
2007; 480 V, 5 ms, 1 Hz). A sequence of four pulses was 
applied, followed by additional four pulses with the reverse 
polarity. An electronic switch cut the pulse as soon as their 
intensity reached 5A to protect against current surges. 
 
Non-invasive  stereomicroscopic  fluorescence  imaging 
of live animals 
GFP expression  in  the  tumor cells  was  detected directly 
through  the  skin  in  the  anesthetized  animal  by  digitized 
fluorescence  stereomicroscopy.  This  procedure  allowed 
observation  of  GFP  expression  in  the  same  animal  for 
several days. Briefly, mice were anesthetized with 2% (v/v) 
of  isoflurane  and  were  kept  under  anesthesia  during  the 
whole  procedure.  High-magnification  images  were 
obtained  with  an epifluorescence  stereomicroscope  using 
0.8 magnification (Leica MZFL III, Germany) and a cooled 
CCD  camera  (Coolsnap  fx,  Roper  Scientific,  France)  as 
previously described Golzio et al, 2005). A 15 mm2 part of 
the animal was observed, which covered the whole tumor. 
Camera  was  driven  by  the  MetaVue  software  2.6 
(Molecular Devices Corporation, USA) from a PC (Dell, 
France).  The  exposure  time  was  set  at  1  sec  with  no 
binning.  The  fluorescence  emission  was  obtained  with  a 
HBO lamp (Osram, Germany), using either a GFP or a G 
filter  set  (Leica  Microsystems,  Germany).  The  eGFP 
fluorescence from the tumor was measured quantitatively 
for one week, while the Alexa Fluor 546 labeled siRNA 
was detected ex vivo 48 hr after the treatment. 
 
Histological sectioning 
Mice were sacrificed by cervical dislocation at 48 hrs and 
tumors were rapidly  observed by  stereomicroscopy.  The 
tissue  was  then  mounted  in  the  optimum  cutting 
temperature  (OCT)  compound  (Tissue-Tek,  Sakura 
Finetek,  NL),  and  was  frozen  in  liquid  nitrogen  and 
pentane. Thin sections were cut at a 15 µm thickness from 
the  OCT  compound  blocks  using  a  cryostat  (Leica 
CM3050 S) at -20
oC. 
 
Confocal fluorescence microscopy 
Cells and histological sections of tumors were visualized 
by confocal microscopy. GFP and Alexa Fluor 546 signals 
were  detected  with  Zeiss  LMS  inverted  confocal 
microscope equipped with a 488 nm laser for the GFP and 
with a 514 nm laser for the Alexa Fluor 546, using a Zeiss 
X40  objective  (1.3  numerical  aperture,  oil  immersion). 
Laser  power  and  photomultiplier  setting  were  kept 
identical for all samples to make the results comparable. 
Images  were  recorded  and  analyzed  with  the  Zeiss 
LMS510 software (EMBL, Germany). 
Statistical analysis 
For each condition, 3 to 5 independent experiments were 
performed.  Differences  in  percentages  or  relative 
fluorescence levels  between  the various conditions were 
statistically  compared  by  using  unpaired  Student  t-test 
two-sided using  Microsoft Excel software. *0,05<P≤0,1, 
** 0.01<P≤0.05 and ***P≤0.01. 
 
RESULTS 
 
In vitro cell permeabilization and cell viability 
Permeabilization of cells was performed by application of 
long duration electric pulses (EP), which are required to 
load  macromolecules  into  cells.  Permeabilization  of 
B16F10 cells was only detected for electric field values 
higher than a threshold. The threshold value was between 
300  and  400  V/cm  (Figure  1).  At  the  optimum  electric 
field  intensity  (600  V/cm),  cell  viability  (V=95%)  was 
preserved while a large fraction of cells was permeabilized 
(P= 57%). The percentage of  viable permeabilized cells 
PV was 52% +/-15 (PV=P+V-100, i.e. (95%-100)+57%) 
(Teissie et al, 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Electric field intensity effect on permeabilization and 
viability. Percentages of permeabilized cells, cell viability and 
viable permeabilized cells were plotted as a function of the electric 
field intensity. Permeabilization was assayed by the penetration of 
PI in cells and analyzed by flow cytometry (▲). The live cells 
were determined 24 hrs after the treatment by crystal violet 
coloration (■). Error bars represent standard deviation. The 
percentage of viable permeabilized cells were determined by 
calculating (permeabilization (%)+viability(%) –100). 
 
 
 
In vitro electrotransfer of siRNAs 
The  transfer  of  the  eGFP22  siRNA  was  carried  out  by 
electropermeabilization of cells in suspension. We chose 
the electric field value of 600 V/cm shown to give a high 
number of permeabilized and viable cells. The percentage 
of  cells  expressing  eGFP  (GFP  positive  cells)  was 
quantified as function of time (data not shown). Figure 2 
shows relative percentage of cells expressing eGFP 48 hrs 
after  a  single  treatment  as  well  as  the  change  in  mean 
fluorescence intensity. 
 
In  all  control  experiments,  relative  percentages  of  cells 
expressing  the  eGFP  were  not  significantly  changed 
(Figure  2). Indeed, if  an  unrelated  non-silencing  siRNA  
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(negative siRNA) was electrotransferred, no changes in the 
percentage  of  eGFP  positive  cells  were  detected.  As 
expected,  the  electrical  treatment  itself  (+EP)  had  no 
effect.  If  eGFP22  siRNA  (i.e.  anti-eGFP  siRNA  Alexa 
Fluor 546 or anti-eGFP siRNA) was injected without EP 
application, no reduction in the percentage of GFP positive 
cells  was  observed.  When  the  eGFP22  siRNA  were 
electrotransferred  (siRNA  injection+  EP),  a  significant 
decrease  in  the  percentage  of  eGFP  positive  cells  were 
observed.  The  decrease  was  maximal  from  days  2  to  4 
(data  not  shown).  At  day  2,  the  percentage  of  cells 
expressing eGFP decreased to 57.8%±3 for treatment with 
unlabeled siRNA and to 50.8%±3 for the Alexa labeled 
siRNA.  The  relative  mean  fluorescence  intensity  of  the 
population decreased to 45.2%±3 for the unlabeled siRNA 
and to 45.8%±3 for the Alexa labeled siRNA, while the 
relative mean fluorescence intensity of eGFP positive cells 
did not show any detectable change. The effect of siRNA 
was  found  to  be  transient.  The  percentage  of  cells 
expressing eGFP returned to its initial value at day 7 post-
treatment  (data  not  shown).  Alexa  labeled  siRNA 
electrotransfer  (siRNA  anti-eGFP  Alexa  Fluor  546+EP) 
showed the same silencing efficacy on the eGFP expression 
as unlabeled siRNA (Figure 2). This observation validated 
its reliable use in further experiments for the visualization 
of its localization within cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Level of silencing by siRNAs in vitro at 48 hrs. Cells 
in suspension were incubated in the presence of 1.4 µM siRNA 
(either negative siRNA or anti-GFP siRNA, labeled with Alexa 
Fluor 546 or unlabelled) in pulsing buffer. Ten pulses of 5 ms at 
frequency of 1 Hz were applied at 0.7 kV/cm (+EP). Grey bars 
represent relative percentage of GFP expressing cells quantified 
at 48 hrs by flow cytometry. Black bars represent mean 
fluorescence intensity (IF) of the cell population relative to that 
of untreated cells. White bars show mean fluorescence intensity 
of cells, which remain GFP positive after electropulsation 
relative to the one of untreated cells. Error bars represent 
standard deviation. 
 
 
 
Localization  of  the  siRNA  into  cells  after 
electrotransfer in vitro 
Forty  eight hours after pulsing cells with  siRNA, eGFP 
negative cells were sorted out by flow cytometry. These 
cells were observed by confocal microscopy to visualize 
the labeled siRNA localization within cells and to evaluate 
eGFP  expression.  The  results  were  compared  with  cells 
simply  incubated  with the  siRNA  (Figure  3).  No  Alexa 
signal was detected in non-pulsed cells (-EP) (Figure 3, 
upper panels). After electrotransfer of siRNA labeled with 
Alexa  Fluor  546  in  cells  (+EP),  eGFP  signal  in  cells 
reduced as compared with the control cells. Alexa signal 
was  observed  only  in  the  cytoplasm  (Figure  3,  lower 
panels). A strong nuclear labeling of a few ‘dead’ tumor 
cells  was  observed,  suggesting  interaction  between  the 
siRNA or the Alexa Fluor 546 and the DNA of dead cells. 
Thus  a  decrease  in  the  fluorescence  intensity  of  eGFP 
indicates  that  electropermeabilization  resulted  in  free 
cellular loading of labeled siRNA in active form. 
 
 
 
 
 
 
 
Figure 3. Localization of anti eGFP siRNA labeled with Alexa 
Fluor 546 48h after electrotransfer in vitro. Cells in suspension 
were incubated in the presence of 1.4 µM siRNA in the pulsing 
buffer. Ten pulses of 5 ms at frequency of 1 Hz were applied at 
0.7 kV/cm. 48 hr after siRNA electrotransfer (+EP) (lower 
panels), cells were sorted out by flow cytometry and were 
observed by confocal microscopy with x40 objective. A zoomed 
picture of one cell is displayed in small boxes. Non-
electrotransfected cells (-EP) were observed (top) using the same 
acquisition parameters. eGFP constitutively expressed in cells 
was detected with a 488 nm Argon laser (panels on left). Alexa 
Fluor 546-labeled siRNAs were detected with a 514 nm Helium-
Neon laser (central panels). A merged image of the two (panels 
on right) points to the cytoplasmic localization of the siRNA. 
 
 
 
Electrotransfer of siRNAs in vivo 
When  tumors  reached  an  average  diameter  of  5-7mm  a 
labeled  siRNA  directed  against  the  eGFP  gene  (Alexa 
Fluor 546 eGFP22 siRNA) or an unrelated non-silencing 
siRNA  (negative  siRNA)  was  injected  slowly  into  the 
mouse  tumor.  Approximately  30  sec  after  injection, 
electric  pulses  were  delivered  at  800  V/cm.  The  higher 
field intensity was needed due to the skin shunting effect 
(Mossop  et  al,  2006).  These  conditions  were  chosen  as 
they were previously shown to induce in vivo both reporter 
gene expression (Rols et al,  1998) and siRNA-mediated 
gene  silencing  in  solid  tumors  with  no  tissue  damage 
(Golzio  et  al,  2007).  As  reported  previously,  a  muscle 
contraction  was  observed  when  an  electric  pulse  was 
applied. Neither local burns nor edema or short or long-
lived loss of functions were observed in our experiments. 
When  the  eGFP22  siRNA  was  electrotransferred  (anti- 
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GFP+EP), a significant decrease in the eGFP ﬂuorescence 
of  the  tumor  was  observed  within  48  hr  following  the 
treatment as observed  by  direct imaging on the animals 
(Figure 4). The decrease was maximal between days 2 to 4 
(data not shown). RNase inhibitor in the injection buffer 
appeared important, as only a non-statistically significant 
decrease  of  the  ﬂuorescence  was  obtained  when  the 
inhibitor  was  absent  (data  not  shown).  The  decrease  of 
eGFP ﬂuorescence observed upon eGFP22 Alexa labeled 
siRNA  electrotransfer was not  observed in  the  different 
control groups (Figure 4). Furthermore, electrotransfer of 
an  unrelated  siRNA  (negative  siRNA)  did  not  lead  to 
changes in eGFP expression as compared with the other 
controls.  As  expected  the  electrical  treatment  itself 
(PBS+EP)  had  no  effect  on  eGFP  expression  in  tumor. 
Interestingly, if no EP were applied after injection of the 
eGFP22  Alexa  labeled  siRNA  (anti-eGFP-EP)  no 
reduction of the eGFP expression relative to controls was 
observed. Thus a synergy between the injection and the 
electrical  treatment  was  needed  for  efficient  delivery  of 
siRNA  into  tumor  cells.  Growth  of  tumors  was  not 
affected  by  any  treatment  (intratumoral  injection  of  the 
siRNA  and/or  EP).  This  confirmed  our  previous  results 
showing the same effect (60% of gene expression decrease 
48 hr after siRNA electrotransfer) using the same siRNA 
sequence  without  the  fluorescent-labeling  (Golzio  et  al, 
2007). These results further demonstrated that the labeling 
of the siRNA did not affect its efficacy, in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. In vivo siRNA electrotransfer in B16F10 eGFP tumors. 
Digital imaging was used to quantify the time lapse ﬂuorescence 
of B16F10 eGFP tumors. For each animal, the mean ﬂuorescence 
of the tumor was quantiﬁed on a relative scale using as a 100% 
reference value the ﬂuorescence intensity measured just before 
treatment (day 0). B16F10 eGFP tumors were injected with 
either PBS (PBS+EP) or unrelated siRNA (negative siRNA+EP) 
both injections followed by electrical treatment or injected with 
the eGFP22 siRNA without or with electrotransfer (anti-eGFP). 
Differences in ﬂuorescence levels between conditions were 
statistically compared by using an unpaired t-test two-sided using 
the Excel software. **0.05<P<0.01 were plotted when observed. 
No statistically signiﬁcant differences (P>0.05) in mean eGFP 
ﬂuorescence levels were observed between the various samples. 
Vertical bars represent standard deviation. The number of mice 
was from three to nine. 
Biodistribution  of  the  siRNA  after  electrotransfer  in 
the tumor 
Forty  eight  hours  after  the  treatment,  the  mice  were 
euthanatized. The tumors were removed and visualized by 
fluorescence stereomicroscopy. No signal of Alexa Fluor 
546 was detected in the non-pulsed tumors (-EP) (Figure 
5, upper panels). After electrotransfer of the Alexa labeled 
siRNA  (+EP),  GFP  fluorescence  in  the  tumors  was 
reduced as compared with the control tumors. Moreover, 
the  Alexa  signal  was  observed  to  be  homogeneously 
distributed in tumors (Figure 5, lower panels). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Observation of the anti-eGFP siRNAs labeled with 
Alexa Fluor 546 after electrotransfer in tumors. 48 hr after 
electrotransfer (+EP) the tumors were removed and observed 
under stereo-microscopy, and were compared with the non-
electrotransfected tumors (-EP). Left panels, constitutively 
expressed eGFP; middle panels, siRNA labeled with Alexa Fluor 
546; right panels, merged image of left and middle panels (which 
emphasizes uniform distribution of the siRNA in the tumor). 
 
 
 
Localization  of  the  siRNA  after  electrotransfer  in 
tumors 
Histological sections of frozen tumors were observed by 
confocal microscopy to visualize the expression of eGFP 
and the localization of labeled siRNAs in the cells (Figure 
6).  No  Alexa  fluorescence  was  detected  in  non-pulsed 
tumors (-EP) (Figure 6, upper half). After electrotransfer of 
the Alexa labeled siRNA (+EP), the eGFP signal  of the 
cells  reduced  as  compared  with  the  control  cells.  The 
distribution  of  the  siRNA  was  homogeneous  in 
electrotransfected tumors, both in the middle as well as on 
the  periphery.  At  cellular  level,  the  Alexa  signal  was 
observed only in the cytoplasm (Figure 6, Lower half). A 
strong nuclear labeling of a few tumor cells was observed 
which was consistent with the similar observations in vitro 
in dead cells. 
 
DISCUSSION 
 
RNAi mediated gene-silencing has emerged as a powerful 
approach for gene function analysis in mammalian cells. 
Furthermore,  the  high  efficacy  of  RNAi  approaches  and 
fewer side-effects makes them an attractive alternative to 
antisense oligonucleotides and ribozymes for nucleic acid-
based therapies. There are two potential therapeutic RNAi 
strategies: First approach involves sustained production of  
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inhibitory RNAs, conferred by replicons, such as plasmids 
or  viral  vectors.  This  approach  faces  the  difficulties 
encountered by conventional gene therapy methodologies 
and  those  associated  with  the  use  of  viral  vectors.  The 
second  approach  is  based  on  exogenous  delivery  of 
chemically  synthesized  siRNAs,  which  presents  the 
advantage of terminating the therapeutic treatment in the 
case  of  a  side-effect, which  is  not  possible  for  methods 
involving  replicon-based  delivery.  A  lowering  in 
production costs of siRNAs in the past few years further 
makes them attractive alternatives to small molecule drugs. 
The main obstacle to the therapeutic application of siRNAs 
is their in vivo delivery. Thus there remains the need of an 
efficient  intracellular  delivery  method  (Dykxhoorn  et  al, 
2006; Rossi, 2005; Xie et al, 2006). Electric pulses induce a 
major  reorganization  of  the  plasma  membrane  of  cells 
leading to a transient "permeabilized" state (Golzio et al, 
2002). This physical technique has been previously used by 
different groups, including ours, to locally deliver siRNAs 
in  various  tissues  (Takabatake  et  al,  2005  Golzio  2005, 
2007;  Zhang  et  al,  2002).  As  previously  reported,  we 
observed  that  the  electrical  treatment  for  reversible 
permeabilization had no detectable effect on tumor growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Localization of the anti eGFP siRNAs labeled with 
Alexa Fluor 546 after electrotransfer in tumors. Forty eight hours 
after the electrotransfer of the siRNA (+EP) (lower half), the 
tumors were removed, sliced and observed under a confocal 
microscope with x40 objective at 0.7 magnification. Non-
electrotransfected tumors (-EP) were (top half) compared with 
electrotransfected tumors. The eGFP expression in cells was 
detected with a 488 nm Argon laser (left) and the siRNAs labeled 
with Alexa Fluor 546 were detected with a 514 nm Helium-Neon 
laser (centre). A merged image of the left and middle panels is 
shown on in the right panels in order to localize siRNAs. 
In  this  study,  we  investigated  approaches  to  tracking 
siRNA  upon  electrodelivery.  Furthermore,  we  defined 
experimental  systems  to  visualize  and  quantify  down-
regulation  of  a  constitutively  expressed  eGFP  reporter 
gene, and the localization of siRNAs in subcutaneous B16-
F10  melanoma  tumors  using  fluorescence  imaging.  A 
similar  imaging  approach  was  previously  used  in  ovo 
(Pekarik et al, 2003). 
 
We observed that permeabilization of murine melanoma 
cells  could  be  achieved  by  application  of  long  electric 
pulses, which have been shown to be required for loading 
macromolecules  into  cells  (Cemazar  and  Sersa,  2007; 
Golzio  et  al,  2007;  Rols  et  al,  1998).  As  previously 
observed  in  many  systems,  in  vitro  permeabilization  of 
B16F10 cells was only detected for electric field values 
higher than 300 V/cm (Figure 1). Under such electric pulse 
conditions,  cell  viability  was  only  slightly  affected  by 
increasing  electric  field  intensity.  The  optimum  electric 
field intensity (600V/cm) was selected by calculating the 
percentage of viable permeabilized cells (52%+/-15).  
 
eGFP  signal  in  cells  electrotransfected  with  siRNAs 
decreased in the regions of 51% to 57% of the total eGFP 
expressing  cells.  This  suggests  that  the  level  of  eGFP 
expression  decreased in  most  viable  cells that  had  been 
permeabilized. This observed silencing was neither due to 
the electric treatment nor the siRNAs alone: Without the 
application of the electric field, siRNAs failed to enter the 
cells (Figure 3), and did not show detectable silencing of 
eGFP expression (Figure 2); furthermore, the electric field 
alone had no effect on eGFP expression. When the siRNA 
was electrotransferred, the percentage of eGFP expressing 
cells decreased significantly at 48 hrs (Figure 2) and the 
Alexa fluorescence was visualized homogeneously in the 
cytoplasm of the electro-treated cells (Figure 3). This is in 
agreement with the cytoplasmic localization of its target 
(mRNA)  (Berezhna  et  al,  2006;  Matsuda  and  Cepko, 
2004). No siRNA was detected in the nucleus of viable 
cells although it showed considerable affinity for nuclei of 
dead  cells  (Figure  6).  The  silencing  of  the  eGFP 
expression was significant at 48 hrs as predicted from the 
life  time  of  the  eGFP:24hrs  (Corish  and  Tyler-Smith, 
1999).  The  effectiveness  of  the  anti-eGFP 
electrotransferred  siRNA  labeled  with  Alexa  Fluor  546 
was transient (data not shown). This could be explained by 
the short lifetime  of this siRNA (that did not carry any 
stabilizing  chemical  modification),  which  could  be 
degraded by intracellular nucleases (Corey, 2007; Elmen 
et al, 2005; Mook et al, 2007). Moreover, the intracellular 
concentration of siRNAs is also expeted to decrease during 
cell division (Paroo and Corey, 2004). 
 
Our study of siRNA delivery by electropulsation showed 
that  siRNA  molecules  had  a  direct,  free  access  to  the 
cytoplasm (Figures 3 and 6). The other non-viral, chemical 
delivery  methods  (such  as  those  involving  the  use  of 
nanoimmunoliposomes and polyethyleneimine), the uptake 
mechanism appears to involve the endocytosis pathway, in 
which siRNA molecules had to escape from the endosomal 
compartment to access the target mRNAs in the cytoplasm 
(Pirollo  et  al,  2007;  Jiang  et  al,  2008).  Electrodelivered 
siRNAs  were  thus  directly  available  to  interact  with  the  
©The Authors | Journal of RNAi and Gene Silencing | May 2008 | Vol 4, No 1 | 281-288 | OPEN ACCESS 
287 
target mRNAs.  We anticipate that this  direct access  may 
help  reduce  the  induction  of  off-target  effects  but  this 
requires further investigation (Crombez et al, 2007).  
 
We  also  followed  the  effect  of  electrical  treatment  on 
knockdown of eGFP expression knockdown with siRNAs, 
in vivo. In agreement with a previous report by Filleur et al 
(2003),  we  did  not  observe  any  detectable  reduction  in 
eGFP  expression  after  intratumoral  injection  of  the 
eGFP22  siRNA  alone  (Figures  3).  eGFP  expression 
knockdown  was  only  observed  on  the  application  of 
electric pulses. The fluorescence imaging data showed that 
electrical treatment was essential for intracellular uptake 
of  the  siRNA  following  direct  intratumoral  injection.  A 
key  observation  was  that  siRNA  appeared  distributed 
homogeneously  throughout  the  cytoplasm  of  the  tumor 
tissue cells. This suggests that the siRNAs were not being 
trapped  in  endosomal  compartments.  Furthermore, 
electrotransfer  appeared  to  be  affecting  all  cells  in  the 
pulsed volume as a strong inhibition was monitored up to 
two days after the treatment. 
 
CONCLUSIONS 
 
The  direct  access  to  the  cytoplasm  by  siRNAs  after 
electrotransfer  emphasizes  that  this  electro-physical 
method is a powerful tool for effective siRNA delivery, ex 
vivo and in vivo. 
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